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Abstract
Context: We set out to characterize the dynamics of islet autoantibodies over the first 
15 years of life in children carrying genetic susceptibility to type 1 diabetes (T1D). We also 
assessed systematically the role of zinc transporter 8 autoantibodies (ZnT8A) in this context.
Design: HLA-predisposed children (N  =  1006, 53.0% boys) recruited from the general 
population during 1994 to 1997 were observed from birth over a median time of 14.9 years 
(range, 1.9-15.5 years) for ZnT8A, islet cell (ICA), insulin (IAA), glutamate decarboxylase 
(GADA), and islet antigen-2 (IA-2A) antibodies, and for T1D. 
Results: By age 15.5 years, 35 (3.5%) children had progressed to T1D. Islet autoimmunity 
developed in 275 (27.3%) children at a median age of 7.4 years (range, 0.3-15.1 years). 
The ICA seroconversion rate increased toward puberty, but the biochemically defined 
autoantibodies peaked at a young age. Before age 2 years, ZnT8A and IAA appeared 
commonly as the first autoantibody, but in the preschool years IA-2A– and especially 







/article/105/12/e4638/5901133 by guest on 05 January 2021
The Journal of Clinical Endocrinology & Metabolism, 2020, Vol. 105, No. 12 e4639
continued to appear steadily until ages 10 to 15  years. Inverse IAA seroconversions 
occurred frequently (49.3% turned negative) and marked a prolonged delay from 
seroconversion to diagnosis compared to persistent IAA (8.2 vs 3.4 years; P = .01).
Conclusions: In HLA-predisposed children, the primary autoantibody is characteristic 
of age and might reflect the events driving the disease process toward clinical T1D. 
Autoantibody persistence affects the risk of T1D. These findings provide a framework 
for identifying disease subpopulations and for personalizing the efforts to predict and 
prevent T1D.
Freeform/Key Words: type 1 diabetes, prediction, children, HLA, islet autoantibodies, dynamics
Before the manifestation of clinical type 1 diabetes (T1D), 
autoantibodies against islet autoantigens are usually de-
tected in the circulation of prediabetic individuals. They 
are considered to reflect ongoing disease activity and are 
useful tools for identifying individuals at risk for T1D (1). 
The disease risk is notably increased in the presence of 2 
or more biochemical autoantibodies when compared to ra-
ther nonprogressive islet autoimmunity characterized by 
positivity for a single autoantibody (2, 3). More than 80% 
of multipositive individuals progress to clinical diabetes in 
15 years, although the pace of progression is highly variable 
(2). Autoantibody titer and affinity, and different antibody 
combinations, have been observed to increase the prognostic 
value of autoantibody testing in the prediction of T1D (3-5).
Both genetic predisposition, mainly determined by the 
human leukocyte antigen (HLA) class II genes, and envir-
onmental factors, play an important role in the disease 
process leading to autoimmunity and eventually to clinical 
disease (6). Genetic polymorphisms both in HLA and non-
HLA genes contribute to the initiation of autoimmunity as 
well as to the progression to overt diabetes (7). The dis-
ease process beginning usually with either autoantibodies 
to insulin (IAA) or to glutamic acid decarboxylase (GADA) 
as the first autoantibody shows different characteristics of 
islet autoimmunity and genetic associations, implicating 
heterogeneity of the disease process (8-12). The primary 
autoantibody signature might predict the disease progres-
sion and the timing of the disease presentation.
At present, the screening for HLA-conferred disease risk 
and islet autoantibodies provides the most reliable and ac-
cessible means to stratify children into risk categories for 
T1D and to identify individuals for future intervention 
trials aimed at preventing or delaying the onset of overt dis-
ease (3). However, despite extensive research efforts auto-
antibody testing and genetic screening are far from being 
a perfect tool for assessing individual diabetes risk or the 
timing of the manifestation of clinical disease. Accordingly, 
there is a need for more information on the natural dy-
namics of disease-associated autoantibodies in childhood 
to better distinguish between nonprogressive immuno-
logical activation and true progressive autoimmunity, and 
to further elucidate the mechanisms underlying the hetero-
geneity of the disease process.
In this prospective study we characterized the dynamics 
of islet autoantibodies during the first 15  years of life. 
We have previously reported seroconversion dynamics of 
diabetes-associated autoantibodies by ages 2 and 5 years 
in the same study cohort (13, 14). In the present analysis 
we put special emphasis on age-dependent differences in 
the seroconversion rate of individual autoantibodies, the 
predictive value of autoantibody testing for clinical T1D, 
the role of primary autoantibody signatures in disease pro-
gression, and the possible disappearance of autoantibodies 
during childhood. We also examined the value of islet cell 
antibodies (ICA) in disease prediction as a part of the auto-
antibody repertoire and assessed systematically the role of 
zinc transporter 8 autoantibodies (ZnT8A) in this context.
Materials and Methods
Study participants and their samples
The study individuals were participants in the Finnish 
population-based Type 1 Diabetes Prediction and 
Prevention (DIPP) study that aims at monitoring the ap-
pearance of islet autoantibodies in children with increased 
HLA-conferred susceptibility to T1D and at identifying 
means to prevent or delay the onset of overt disease in 
at-risk individuals. The DIPP Study is an ongoing ob-
servational birth cohort study in the Turku, Oulu, and 
Tampere University Hospitals. The study protocol has 
been described in detail in our earlier reports (3, 15). In 
brief, the children were seen every 3 to 6 months during 
the first 2 years and every 6 to 12 months thereafter, un-
less they turned autoantibody positive, in which case moni-
toring continued every 3 months. The first study visit took 
place at age 3 months. Every effort was made to minimize 
the dropout rate during the 15-year follow-up. At clinical 
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blood sampling to prevent discomfort and pain. If a partici-
pant missed an appointment, the families were encouraged 
to contact the research nurse to reschedule the visit. The 
study visits were free of charge.
In the present study, the first 1006 children (53.0% boys) re-
cruited to the DIPP Study, born between November 1994 and 
July 1997, were observed up to a maximum age of 15.5 years 
for the development of ICA, IAA, GADA, ZnT8A, and auto-
antibodies to islet antigen-2 (IA-2A). Follow-up visits taking 
place after age 14.5 years were considered as the final 15-year 
visits. Autoantibody samples obtained before age 15.5 years 
were included in the detailed autoantibody analyses.
Genetic screening
The eligible participants carried either the high-risk HLA 
genotype DQB1*02/*0302 or the moderate-risk genotypes 
DQB1*0302/x (x≠*02, *0301, or *0602) (16, 17). Screening 
for the HLA-DR/DQ risk haplotypes was performed on 
cord blood by using polymerase chain reaction amplification 
followed by time-resolved fluorometry (16-18).
Autoantibody analyses
The diabetes-associated autoantibodies were analyzed in the 
Research Laboratory, Department of Pediatrics, University 
of Oulu, Oulu, Finland, except for ZnT8A, which were 
analyzed in the PEDIA laboratory, University of Helsinki, 
Helsinki, Finland. ICA were analyzed using an indirect im-
munofluorescence staining method, as previously described 
(19). The detection limit for ICA positivity was 2.5 Juvenile 
Diabetes Foundation units (JDFU). Standardization of the 
ICA assay has been described in the Supplemental Methods 
(20). The biochemical autoantibodies IAA, GADA, IA-2A, 
and ZnT8A were measured with specific radiobinding as-
says, described in detail previously (21-25). Study samples 
with autoantibody titers between the 97th and 99.5th per-
centile values of the reference population comprising 370 
to 374 nondiabetic Finnish children were reanalyzed to 
confirm the result. Based on the results from the Diabetes 
Autoantibody Standardization Program and the Islet 
Autoantibody Standardization Program in 2010 to 2016, 
the sensitivities of the IAA, GADA, IA-2A, and ZnT8A 
radiobinding assays have been 36% to 62%, 64% to 88%, 
62% to 72%, and 62% to 70%, respectively, and the cor-
responding specificities have been 94% to 98%, 94% to 
99%, 93% to 100%, and 99% to 100%, respectively.
Definitions
Seroconversion to confirmed autoantibody positivity was 
defined as testing positive for the autoantibody in at least 
2 consecutive samples. The date of seroconversion was de-
fined as the date of draw of the first autoantibody-positive 
sample. Multipositivity was defined as simultaneous posi-
tivity for at least 2 autoantibodies in 2 consecutive samples. 
Only autoantibodies turning positive before the diagnosis 
of clinical T1D were included in the detailed autoanti-
body analyses. Infants with maternal autoantibodies were 
excluded from the autoantibody analyses if no de novo 
production of islet autoantibodies was detected. T1D was 
diagnosed according to the World Health Organization cri-
teria (26). Progressors were defined as individuals who had 
been diagnosed with T1D. Inverse seroconversion was de-
fined as turning permanently autoantibody negative after 
testing autoantibody positive in at least 2 consecutive sam-
ples. Fluctuating autoantibody positivity was defined as 1 
or more autoantibody negative samples between positive 
samples, that is, at least 2 consecutive positive samples be-
fore and after the negative samples. Autoantibody titers 
were compared among individuals positive for the specific 
autoantibody reactivity.
Data analysis
IBM SPSS Statistics 25.0 statistical software for MacIntosh 
was used for multiple parametric and nonparametric statis-
tical analyses. The CI was set at 95% and the 2-tailed statis-
tical significance was set at P less than .05. Cross-tabulation, 
the Pearson χ 2 test, the Fisher exact test, the Mann-Whitney 
U test, and the Kruskal-Wallis test were applied to test stat-
istical differences, when applicable. Survival distributions 
were tested by using the log-rank test. Survival tables were 
created by using the GraphPad Prism 8 software for Mac 
OS X. Sensitivity and specificity values were determined as 
previously described (27), and the corresponding 95% CIs 
were calculated by using a web-based statistical software 
(http://statpages.info/ctab2x2.html). Missing data were ex-
cluded from the analyses. Corrections for multiple testing 
were not applied in the present data analysis because of 
the overly conservative nature of the Bonferroni correction. 
The achieved results were, however, interpreted cautiously, 
taking into account that the null hypotheses may have been 
falsely rejected by chance because of the multiple testing.
Ethical considerations
The legal representatives of the study participants have 
given written informed consent for HLA-screening and 
for participation in the DIPP Study. The study protocol 
has been approved by the local ethics committees of the 3 
participating hospitals, and the study has been carried out 
according to the principles of the Declaration of Helsinki 
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Results
Description of the study cohort
The study participants were observed from birth over 
a median time of 14.9  years (range, 1.9–15.5  years), 
including progressors to T1D (20). Altogether 542 (55.8%) 
nonprogressors completed the 15-year follow-up (Fig. 1). 
By age 15 years, 35 (3.5%) children had progressed to T1D. 
Altogether 275 (27.3%) children had confirmed serocon-
version to autoantibody positivity, including 32 progressors. 
In addition, 2  progressors had their first autoantibody-
positive sample at diagnosis. Both of them had dropped 
out from the autoantibody follow-up several years before 
the diagnosis (3.6 and 10.4  years). By age 15  years, the 
relative proportions of the HLA risk groups remained 
essentially unaltered, with 136 children (25.1%) in the 
high-risk and 406 (74.9%) in the moderate-risk group. The 
proportion of progressors was higher in the high-risk than 
in the moderate-risk HLA group (8.3 vs 1.9%; P < .001). 
Although there was no difference in the sex distribution be-
tween progressors and nonprogressors, a higher proportion 
of progressors were boys after age 10 years compared to 
younger progressors (n = 10, 83% vs n = 9, 39%; P = .03). 
At birth, 5 (14%) progressors and 31 (3%) nonprogressors 
had a first-degree relative affected by T1D (20).
Appearance of diabetes-associated 
autoantibodies
The overall seroconversion rate increased over the first 
15.5  years, mostly because of ICA seroconversions 
(Table  1). When ICA was omitted from the screening 
repertoire, the age at seroconversion decreased (20). 
Children carrying the high-risk HLA genotype devel-
oped autoantibodies more frequently than those with 
moderate-risk genotypes (36 vs 24%; P < .001; screening 
without ICA 18 vs 9%; P < .001). Among the serocon-
verted children, we observed no statistically significant 
differences in the frequency of ZnT8A, IA-2A, or ICA 
positivity between the HLA genotypes, but the develop-
ment of IAA and GADA positivity showed higher fre-
quency among those with the high-risk genotype (data 
not shown). There were no sex differences in the overall 
seroconversion rate when approaching puberty (data 
not shown). Autoantibody characteristics among the 
progressors and nonprogressors are presented in Fig. 2 
and Supplemental Table 2 (20).
The dynamics of islet autoantibodies
All antibodies demonstrated increasing cumulative pro-
portions up to age 15 years (see Fig. 1). To assess the dy-
namics of autoantibodies, we calculated seroconversion 
rates in the age periods 0 to 2, 2 to 5, 5 to 10, and 10 to 
15.5 years (Table 1). The primary ICA seroconversion rate 
increased continuously toward puberty, but primary sero-
conversions positive for IAA and ZnT8A peaked already 
before age 2 years, and in the case of IA-2A between ages 
2 and 5  years, whereas GADA-positive seroconversions 
demonstrated a steady rate up to between ages 10 and 
15.5 years (20).
Development of multipositivity
The proportion of multipositive children increased 
steadily over the first 15  years (20). However, only 4 
children developed multipositivity for biochemical auto-
antibodies after age 10 years. Children with the high-risk 
HLA genotype demonstrated significantly more often 
multipositivity than those with moderate-risk genotypes 
(data not shown). The appearance of multiple biochem-
ical autoantibodies conferred a 58% risk of developing 
clinical diabetes in the next 10  years (95% CI, 44%-
71%). Intriguingly, the presence of ZnT8A in the first 
sample positive for multiple biochemical autoantibodies 
was associated with a higher 10-year risk of clinical dia-
betes (73.1%, n = 19; 95% CI, 54%-87%) than the ab-
sence of ZnT8A on this occasion (40.0%, n  =  8; 95% 
CI, 22%-61%; P  =  .02). Season of birth contributed to 
Figure 1. Development of islet cell (ICA), insulin (IAA), glutamate de-
carboxylase (GADA), islet antigen-2 (IA-2A), and zinc transporter 8 
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age at multipositivity; participants born in the winter 
(December to February) tested more often multipositive 
for biochemical autoantibodies before age 2 years (67 vs 
25%; P = .004) and tended to develop multipositivity for 
biochemical autoantibodies at a younger age than those 
born in other seasons (median, 1.5 vs 4.0 years; P = .06).
Inverse seroconversions and fluctuating 
autoantibodies
Among the islet autoantibodies, IAA demonstrated most 
often inverse seroconversions and fluctuations (Table  2, 
[20]). No inverse seroconversions or fluctuations of ICA 
occurred in progressors. None of the children with multiple 
biochemical autoantibodies turned completely autoanti-
body negative by age 15.5 years, although one of them had 
only ICA in the last sample available. The rate of inverse 
IAA seroconversions was higher among children born in 
the fall (September to November) than among those born 
in other seasons (77 vs 43%; P = .03).
Effect of autoantibody titers on inverse 
seroconversions
Because IAA and ICA experienced inverse seroconversions 
and fluctuating patterns most frequently, we examined the 
association of their peak titers with the rate of inverse 
seroconversions. For every child who tested positive for 
ICA and/or IAA, the maximum autoantibody titer for 
each reactivity was used. The peak IAA titers were higher 
among those who remained IAA-positive (median 34.6 
[n = 35] vs 11.0 [n = 34] relative units [RU]; P < .001). 
Similarly, the peak ICA titers were higher among those 
with persistent ICA (median 10.0 [n = 168] vs 5.0 [n = 77] 
JDFU; P < .001).
Comparison of progressors to multipositive 
nonprogressors
We compared the progressors to nonprogressors who de-
veloped multipositivity. A higher proportion of progressors 
tested multipositive within a year from seroconversion, 
although this difference turned out to be statistically 
nonsignificant, when ICA was removed from the analysis 
(20). Without ICA in the analysis, the progressors tested 
more often positive for IAA at seroconversion especially 
before age 5  years, had more stable IAA positivity, and 
developed ZnT8A positivity at a younger age than the 
multipositive nonprogressors. The titers of ICA, IA-2A, 
and ZnT8A were significantly higher in progressors al-
ready several months before diagnosis when compared to 
matched multipositive controls (20).
Primary autoantibodies at seroconversion
Autoantibody profiles at initial seroconversion demon-
strated distinct characteristics in different age groups 
(Fig.  3). Consistently with the age-related profiles, 
Table 1. Cumulative frequencies of autoantibodies by age 15.5 years, median age at seroconversion, and seroconversion 
rates in 4 age periods (0-1.99, 2-4.99, 5-9.99, and 10-15.5 years)
Autoantibody type Cumulative frequency  
of autoantibody at 15.5 y, %a
Median age at 
seroconversion (range), y
Seroconversions/100 follow-up, y
0-1.99 2-4.99 5-9.99 10-15.5
ICA ≥ 2.5 JDFU 245 (24.4) 8.1 (0.5-15.1) 1.2 1.5 2.3 2.8
ICA ≥ 10 JDFU 72 (7.2) 4.2 (0.5-14.5) 1.1 0.6 0.5 0.4
ICA ≥ 20 JDFU 50 (5.0) 4.2 (0.8-12.7) 0.7 0.5 0.4 0.2
IAA 69 (6.9) 2.5 (0.5-14.0) 1.4 0.6 0.4 0.2
GADA 69 (6.9) 5.0 (0.8-12.9) 0.9 0.6 0.6 0.3
IA-2A 42 (4.2) 4.1 (1.0-12.1) 0.5 0.6 0.3 0.1
ZnT8A 48 (4.8) 3.1 (0.3-15.0) 0.8 0.6 0.3 0.1
At least 1 autoantibody 275 (27.3) 7.4 (0.3-15.1) 2.0 1.8 2.5 2.7
At least 1 autoantibody, ICA ≥ 10 
JDFU
126 (12.5) 4.0 (0.3-14.5) 2.0 1.2 0.9 0.5
At least 1 autoantibody, ICA ≥ 20 
JDFU
113 (11.2) 4.0 (0.3-14.0) 1.7 1.0 0.9 0.5
At least 1 biochemical autoantibody 113 (11.2) 4.0 (0.3-14.0) 1.7 1.1 0.9 0.5
Multiple (≥ 2) autoantibodies 71 (7.1) 4.0 (0.8-14.4) 1.1 0.6 0.5 0.4
Multiple biochemical autoantibodies 50 (5.0) 3.0 (0.8-12.1) 1.0 0.5 0.3 0.1
Abbreviations: IAA, insulin autoantibodies; IA-2A islet antigen-2 autoantibodies; ICA, islet cell antibodies; GADA, glutamate decarboxylase autoantibodies; JDFU, 
Juvenile Diabetes Foundation units; ZnT8A, zinc transporter 8 autoantibodies.
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the primary autoantibodies present at seroconversion 
showed notable differences between the progressors and 
nonprogressors (Tables 3 and 4). The primary single auto-
antibody among progressors was predominantly IAA or 
ZnT8A, whereas in multipositive nonprogressors this was 
mainly GADA. ICA as a single autoantibody at seroconver-
sion indicated nonprogressive autoimmunity regardless of 
the ICA titer.
Progression rate to overt type 1 diabetes
Although the number of progressors was relatively modest, 
we examined the associations of autoantibodies with the 
pace of disease progression. Among progressors, inverse 
seroconversions to IAA were associated with a prolonged 
delay from seroconversion to diagnosis when compared to 
persistent IAA positivity (8.2 [n = 7] vs 3.4 [n = 20] years; 
P =  .01). At diagnosis, IAA positivity was more common 
among participants with the high-risk HLA genotype than 
among those with moderate-risk genotypes (75 [n = 15] vs 
36% [n = 5]; P =  .02). Those who tested IAA positive at 
diagnosis were younger at disease presentation than those 
who tested IAA negative on this occasion (median, 6.6 
[n = 20] vs 11.4 [n = 11] years; P =  .04), although there 
was no difference in age at seroconversion between these 
groups (1.6 [n = 20] vs 1.3 [n = 11] years; P = .52). Other 
autoantibodies at diagnosis were not associated with age at 
diagnosis (data not shown). Autoantibody data at the diag-
nosis of T1D are presented in Supplemental Table 6 (20).
The role of islet cell autoantibodies in disease 
prediction
Sensitivities, specificities, and positive predictive values 
for predicting clinical T1D of individual autoantibodies 
and multipositivity with and without ICA are compiled in 
Supplemental Table 7 (20). We examined several thresholds 
for ICA positivity to assess whether the ICA titer affected 
the prediction of T1D. Among multipositive children, there 
were no ICA-negative children, whereas only 48 (68%) 
children had IAA, 52 (73%) GADA, 40 (56%) IA-2A, and 
43 (61%) ZnT8A. Without ICA in the analysis, 21 (29.6%) 
multipositive children would have been missed. One of 
these children progressed to T1D and tested multipositive 
for biochemical autoantibodies at diagnosis. The initial ICA 
titer in this child was 10 JDFU. Most ICA-positive children 
remained negative for the biochemical autoantibodies, but 
high ICA titers increased the proportion of overlap (20). 
Most children with biochemical autoantibodies tested ICA 
positive in 15 years, and the titers of ICA were relatively 
high in these individuals.
Discussion
Here we explored the natural dynamics of diabetes-
associated autoantibodies by age 15 years in 1006 children 
with HLA-conferred susceptibility to T1D derived from the 
general population in Finland with the highest disease in-
cidence in the world. We have previously reported 2- and 
5-year follow-up data from the same cohort (13, 14). In the 
present study, we demonstrate that the primary autoanti-
body profiles are characteristic of age, and that ZnT8A may 
appear early in the disease process. In young children, β-cell 
autoimmunity often begins with IAA or ZnT8A positivity. 
GADA-initiated β-cell autoimmunity commonly appears 
later. ICA becomes the prevailing autoantibody toward pu-
berty after the preschool years and if remaining as a single 
autoantibody does not have any value for predicting T1D. 
The biochemical autoantibodies show decreasing serocon-
version rates with increasing age. There are no differences 
in seroconversion rates between boys and girls with aging. 
The proportion of multipositive children increases steadily 
over the first 15 years, although progression to biochem-
ical autoantibody multipositivity rarely occurs after age 
10  years. Among the islet autoantibodies, inverse sero-
conversions and fluctuations of IAA are most common. 
Figure 2. Autoantibodies at initial seroconversion among progressors 
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Accordingly, our findings are in line with previous char-
acterizations of IAA appearing early but being rather un-
stable (9-14, 28, 29).
The strengths of this study are the general population-
based study cohort and the regular autoantibody follow-up 
starting from birth, enabling close collaboration with the 
participating families. With respect to other extensive longi-
tudinal follow-up studies, such as Type 1 Diabetes TrialNet 
or The Environmental Determinants of Diabetes in the 
Young (TEDDY), this is the first systematic prospective 
Table 2. Inverse seroconversions and fluctuating autoantibodies in study cohort
Total Progressors Autoantibody-positive 
nonprogressors
Pg
N (%)a N (%)b N (%)c
Inverse seroconversions  124 (45.1) 13 (40.6) 111 (45.7) .59
Fluctuating autoantibodies  110 (40.0) 12 (37.5) 98 (40.3) .76
Multiple fluctuations of same reactivity  49 (17.8) 8 (25.0) 41 (16.9) .26
Inverse seroconversions and/or fluctuations  180 (65.5) 21 (65.6) 159 (65.4) .98
Inverse seroconversions and fluctuations  54 (19.6) 4 (12.5) 50 (20.6) .28
  N (%)d N (%)e N (%)f  
Inverse seroconversion ICA 77 (31.4) 0 (0) 77 (36.2) < .001
IAA 34 (49.3) 7 (25.9) 27 (64.3) .002
GADA 20 (29.0) 5 (20.0) 15 (34.1) .22
IA-2A 4 (9.3) 0 (0) 4 (22.2) .01
ZnT8A 9 (18.8) 3 (12.0) 6 (26.1) .21
Fluctuating positivity ICA 69 (28.2) 0 (0) 69 (32.4) < .001
IAA 25 (36.2) 7 (25.9) 18 (42.9) .15
GADA 14 (20.3) 1 (4.0) 13 (29.5) .01
IA-2A 6 (14.0) 2 (8.0) 4 (22.2) .18
ZnT8A 8 (16.7) 6 (24.0) 2 (8.7) .16
 Median (range)    
Median age at inverse seroconversion, y ICA 13.0 (1.0-15.4) NA NA NA
IAA 6.9 (1.3-13.7) 6.2 (1.8-10.6) 7.1 (1.3-13.7) .48
GADA 10.6 (1.5-14.3) 2.1 (1.5-9.7) 11.3 (5.7-14.3) .006
IA-2A 9.1 (2.8-10.0) NA NA NA
ZnT8A 4.0 (2.0-14.8) 4.0 (2.6–7.9) 3.9 (2.0-14.8) .61
Median age at first AAB reappearance, y ICA 12.6 (6.5-15.5) NA NA NA
IAA 8.1 (2.0-13.9) 6.3 (4.5-10.8) 8.1 (2.0-13.9) .36
GADA 8.4 (2.3-14.2) 14.2 8.2 (2.3-14.0) .11
IA-2A 8.1 (7.0-14.2) 10.8 (7.4-14.2) 8.1 (7.0-11.3) .64
ZnT8A 2.9 (1.8-9.0) 2.9 (1.8-4.3) 5.5 (2.0-9.0) .51
Time from seroconversion to AAB 
disappearance, y
ICA 2.5 (0.5-9.1) NA NA NA
IAA 2.3 (0.5-13.4) 3.7 (1.3-8.0) 2.2 (0.5-13.4) .69
GADA 5.0 (0.5-9.8) 1.1 (0.9-5.7) 6.0 (0.5-9.8) .06
IA-2A 2.8 (1.0-5.5) NA NA NA
ZnT8A 2.2 (0.5-12.3) 2.2 (1.6-6.9) 3.1 (0.5-12.3) .61
Time from seroconversion to first AAB 
fluctuation, y
ICA 4.0 (0.7-11.5) NA NA NA
IAA 3.8 (0.7-10.4) 3.5 (2.8-8.0) 4.1 (0.7-10.4) .81
GADA 3.5 (1.0-7.2) 7.2 3.5 (1.0-7.0) .11
IA-2A 5.2 (3.5-7.2) 6.8 (6.4-7.2) 4.1 (3.5-6.3) .06
ZnT8A 1.4 (1.0-10.2) 1.4 (1.0-3.8) 5.6 (1.0-10.2) .74
Abbreviations: AAB, autoantibody; IAA, insulin autoantibodies; IA-2A islet antigen-2 autoantibodies; ICA, islet cell antibodies; GADA, glutamate decarboxylase 
autoantibodies; ZnT8A, zinc transporter 8 autoantibodies.
aProportion of seroconverters (n = 275).
bProportion of progressors with confirmed seroconversion (n = 32).
cProportion of autoantibody-positive nonprogressors (n = 243).
dProportion of study participants positive for the specific autoantibody reactivity (see Table 1).
eProportion of progressors positive for the specific autoantibody reactivity (see Supplemental Table 2 [20]).
fProportion of nonprogressors positive for the specific autoantibody reactivity (see Supplemental Table 2 [20]).
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analysis of HLA-predisposed children that includes both 
ICA and ZnT8A in the screening repertoire in addition to 
the 3 other biochemical autoantibodies. Another advantage 
in the DIPP Study is the birth cohort–based ability to deter-
mine seroconversion age in all participants. The number of 
participants in the present study is relatively modest, but al-
lows testing for statistical differences. Taking into account 
the limited size of the initial study population, the dropout 
rate was relatively high but tolerable considering the long 
15-year follow-up. Many children were lost to follow-up 
during the last years of the study period, but at 10 years the 
dropout rate remained reasonable. Owing to the modest 
number of participants, the results should be interpreted 
cautiously. Corrections for multiple testing were not ap-
plied in the present data analysis, which might limit the in-
terpretation of the results. The generalizability of the results 
is limited because all the study participants carry selected 
HLA-risk genotypes for T1D. However, these genotypes are 
found in the majority (62%) of children with T1D (18). 
Another limitation in this study is the lack of data on meta-
bolic characteristics as an indicator for T1D risk.
As a novel finding, ZnT8A appeared commonly in very 
young children and in many cases as the first autoanti-
body even before IAA. Together with IA-2A, ZnT8A had 
the highest specificity for T1D. As the single first autoanti-
body at seroconversion, ZnT8A was strongly predictive 
for clinical disease. At diagnosis, ZnT8A were present in 
66% of progressors, which is consistent with previous re-
ports (25, 30). The titers of ZnT8A together with ICA and 
IA-2A started to rise in progressors already several months 
before diagnosis compared to matched multipositive 
controls. This is in line with earlier observations, stating 
that ZnT8A positivity at diagnosis occurs consistently with 
ICA and/or IA-2A, but less often with positivity for GADA 
or IAA (24, 30, 31). In general, ZnT8A might indicate an 
aggressive disease process. In β cells, ZnT8 is involved in 
insulin secretion, and is a disease-associated autoantigen 
of proinflammatory T cells (32). At diagnosis, ZnT8A 
positivity implies a higher risk of ketoacidosis and pre-
dicts an increased need for insulin after the diagnosis (30). 
Accordingly, our results suggest that ZnT8A appearing 
early in the disease process and as the primary autoanti-
body in young children might be a strong indicator of 
T1D. At diagnosis, ZnT8A positivity has been linked to 
the HLA-DQ8 and DQ6.4 haplotypes, but is inversely as-
sociated with the DR3-DQ2/DR4-DQ8 genotype and the 
DR3-DQ2 haplotype, which might be partly explained by 
differential binding of the DQ molecules to ZnT8 epitopes 
(25, 31, 33, 34). In the present study no association of 
ZnT8A with the HLA genotype was observed, probably 
because of the limited selection of HLA genotypes.
In young children, ZnT8A or IAA emerged commonly as 
the first autoantibody, whereas GADA-initiated islet auto-
immunity increased in the preschool years and continued to 
appear steadily until the pubertal years. The different char-
acteristics of β-cell autoimmunity initiated by either IAA or 
GADA have recently been studied (8-12). The 2 endotypes 
show different genetic associations (8, 9, 35), and the IAA-
first endotype has been related to T1D-linked Coxsackie B1 
infections, whereas primary GADA signature might arise 
from a different etiological background (36). In the present 
study, GADA as the first single autoantibody at serocon-
version was rare among progressors, whereas it was char-
acteristic of multipositive nonprogressors. In contrast, the 
primary autoantibody among progressors was mainly IAA 
or ZnT8A among those who were not multipositive at ini-
tial seroconversion. This highlights the existence of at least 
2 paths of advanced islet autoimmunity and might reflect 
the fact that initial IAA reactivity peaks at a young age, 
whereas GADA appears more evenly over a series of years 
(10-12). In an earlier DIPP study, we compared the pro-
gression from seroconversion to clinical diabetes between 
children with either IAA or GADA as the first autoanti-
body but could not see any difference in the progression 
rate (9). The long follow-up of the whole cohort in the 
present study has especially increased the number of older 
children with GADA-initiated autoimmunity who have not 
yet progressed further. Moreover, the season of birth affects 
the pace of disease progression (15), and might contribute 
to age-related features of β-cell autoimmunity. In the pre-
sent study, positivity for multiple biochemical autoanti-
bodies appeared at a younger age among children born in 
Figure 3. Autoantibody profiles at initial seroconversion in the age 
groups 0 to 2 (N = 41), 2 to 5 (N = 51), 5 to 10 (N = 97), and 10 to 15.5 
(N = 86) years. *P less than .05 compared to all other groups. †P less 
than .05 0 to 2 vs 2 to 5, 0 to 2 vs 5 to 10, 0 to 2 vs 10 to 15.5, 2 to 5 vs 5 
to 10, 2 to 5 vs 10 to 15.5 years. ‡P less than .05 0 to 2 vs 2 to 5, 0 to 2 vs 
5 to 10, 0 to 2 vs 10 to 15.5, 2 to 5 vs 5 to 10 years. §P less than .05 0 to 
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the winter, whereas inverse seroconversions of IAA peaked 
among children born in the fall. The present observations 
together with previous reports support the idea of het-
erogeneity in the triggering events of β-cell autoimmunity 
that might be age-related, linked to the stage of immuno-
logical maturation, the strength of protection by maternal 
antibodies, and the exposure to seasonal environmental 
factors, including infections, which usually become more 
common in the preschool years as children start daycare. It 
is also intriguing to consider whether GADA might, in fact, 
reflect counteracting mechanisms against progressive auto-
immunity. This idea is supported by the observations that 
the autoantigen for GADA, glutamic acid decarboxylase, is 
involved in the production of the anti-inflammatory neuro-
transmitter γ-aminobutyric acid (GABA), which has been 
shown to promote β-cell survival and replication, and to 
increase the human β-cell mass (37).
The loss of IAA reactivity has been associated with 
delayed disease progression in multipositive children (38). 
Although the number of progressors in the present study 
was modest, disease progression turned out to be slower 
when IAA disappeared before diagnosis. This finding raises 
questions as to why autoantibody production against in-
sulin may be attenuated among individuals with delayed 
progression. First, when the loss of IAA positivity reflects 
events in humoral β-cell autoimmunity, cell-mediated auto-
immunity against insulin may still continue. However, 
without the support of humoral immunity the disease 
process might slow down, which suggests that B cells are 
active players in the pathogenesis of T1D (39). Second, in-
dividuals with delayed progression may possess immuno-
logical mechanisms that are capable of hiding the β-cell 
autoantigens from the immune system. In fact, in several 
studies patients with T1D have been described in whom 
C-peptide production has been detectable after decades of 
clinical disease, suggesting that β cells were not completely 
destroyed (40, 41). In contrast to previous observations, re-
version of GADA positivity did not affect the risk of clinical 
diabetes in the present study (42, 43). Reversions of mul-
tiple biochemical autoantibody positivity occurred rarely, 
which is in accordance with earlier reports and supports 
the idea that positivity for multiple biochemical autoanti-
bodies might be seen as an early stage of T1D (44).
ICA is laborious to analyze and the assay is hard to 
standardize, thus replacing ICA with biochemical autoanti-
bodies is enticing. Therefore we analyzed the dynamics of 
ICA in detail and evaluated the impact of excluding ICA 
from the autoantibody repertoire used for screening pur-
poses. ICA had a high sensitivity to identify progressors 
to clinical disease, but in contrast to previously reported 
5-year follow-up data, quite poor specificity compared to 
biochemical autoantibodies (14). This difference probably 
results from the steep increase in the ICA seroconversion 
rate after the preschool years. The significantly higher 
specificity and positive predictive value of positivity for 
multiple biochemical autoantibodies when compared to 
ICA positivity suggest that low-titer ICA can be replaced 
by positivity for multiple biochemical autoantibodies 
when screening for risk of T1D (20, 45, 46). However, if 
the threshold for ICA positivity is set at 10 JDFUs, ICA 
predict T1D and perform in the screening purposes simi-
larly to the biochemical autoantibodies. Because the ICA 
method is biological, using pancreatic tissue, the method 
detects a wide variety of islet-specific antibodies and occa-
sionally other cross-reactive antibodies in serum samples 
(47). Therefore, the ICA method can never be as specific as 
biochemical methods, and for the same reason it is more 
sensitive. In prediabetes screening, by determining the op-
timal JDF level of ICA that provides the best combination 
of sensitivity and specificity, the ICA method can provide 
something more than is available in the 4-biochemical 
autoantibody method set. The increasing ICA seroconver-
sion rate toward adolescence is restricted to low-titer ICA. 
This type of ICA reactivity is not related to the risk of pedi-
atric T1D, but may anticipate the fact that ICA positivity 
is commonly seen in adults (48). Removing low-titer ICA 
from the preclinical screening program in the general popu-
lation would significantly affect the seroconversion age. 
This should be noted when explaining the risk of diabetes 
to physicians and the families of screened children.
Interestingly, none of the present progressors demon-
strated transient or fluctuating ICA. This may reflect the 
fact that ICA reactivity is in part derived from reactions 
toward other islet autoantigens, and also yet undiscovered 
autoantigens may contribute to disease-associated ICA re-
activity (47). In the present study, isolated low-titer ICA 
positivity occurred especially at initial seroconversion 
and the overlap of ICA with biochemical autoantibodies 
was restricted mostly to high ICA titers. Most children 
with biochemical autoantibodies tested positive for high-
titer ICA with advancing age. The highest proportions of 
overlap with ICA were seen in children positive for IA-2A 
and ZnT8A.
Based on studies in the Finnish population, it was es-
timated at the beginning of the DIPP Study that ap-
proximately 7% of the high-risk and 2% to 3% of the 
moderate-risk children would develop T1D by age 15 years 
(18). The proportion of affected children in the high-risk 
(8.3%) and moderate-risk HLA groups (1.9%) match that 
prediction.
To conclude, the proportion of diabetes-associated 
autoantibodies in children HLA-predisposed to T1D in-
creases steadily during the first 15 years of life, mostly 
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autoantibodies and high-titer ICA show decreasing sero-
conversion rates with advancing age. The conspicuous 
differences in the age-related behavior of individual 
biochemical autoantibodies indicate that age and the 
stage of immunological maturation contribute substan-
tially to the characteristics of islet autoimmunity. In 
young children, ZnT8A and IAA are the most common 
primary autoantibodies, but at preschool age GADA-
driven islet autoimmunity increases and continues to ap-
pear steadily until the teenage years. The first-appearing 
autoantibody might reflect the events driving the disease 
process toward overt disease. The fluid state of auto-
antibodies, especially IAA, might impart the risk for 
T1D. These findings provide a valuable framework for 
understanding the disease heterogeneity and for person-
alizing the efforts to predict T1D. Further investigation 
into the age-dependent paths of humoral islet auto-
immunity might provide mechanistic insights into the 
disease process.
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